Investing in Assembly Biosciences, Inc. (ASMB)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)3.32-78
Intrinsic value (DCF)1.27-92
Graham-Dodd Method0.00-100
Graham Formula0.00-100

Company description

ASMB, or Assembly Biosciences Inc., is a clinical-stage biotechnology company that focuses on the development of innovative treatments for hepatitis B virus (HBV) and other viral infections. The company's lead product, ABI-H0731, is currently in Phase 2 clinical trials and has shown promising results in suppressing the HBV virus. ASMB's drug candidate pipeline also includes treatments for other chronic viral infections such as human papillomavirus (HPV), Epstein-Barr virus (EBV), and cytomegalovirus (CMV). The company utilizes its proprietary technology, HepDirect, to deliver antiviral agents directly to the site of infection, improving treatment efficacy and reducing adverse effects. ASMB also has a strategic collaboration with Allergan to develop and commercialize treatments for gastrointestinal diseases caused by viral factors. With a team of experienced researchers and a strong commitment to scientific innovation, ASMB is on a mission to transform the treatment landscape for viral infections and improve the lives of patients worldwide.